Cited by 322Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 35 of the 38 references it cites were found in a registry or an index.

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Open access

Zhou, Caicun, Wu, Lin, Fan, Yun, Wang, Zhehai, Liu, Lianke, Chen, Gongyan, Zhang, Li, Huang, Dingzhi, Cang, Shundong, Yang, Zhixiong, Zhou, Jianying, Zhou, Chengzhi, Li, Baolan, Li, Juan, Fan, Min, Cui, Jiuwei, Li, Yuping, Zhao, Hui, Fang, Jian, Xue, Jianxin, Hu, Chengping, Sun, Ping, Du, Yingying, Zhou, Hui, Wang, Shuyan, Zhang, Wen·2021·Journal of Thoracic Oncology

DOI 10.1016/j.jtho.2021.04.011

Open this paper in CoChat — free account Open PDF

Abstract

Introduction The standard chemotherapy for squamous NSCLC (sqNSCLC) includes platinum plus gemcitabine. Sintilimab, an anti-programmed cell death protein 1 antibody, plus platinum and gemcitabine (GP) has revealed encouraging efficacy as first-line therapy for sqNSCLC in a phase 1b study. We conducted a randomized, double-blind, phase 3 study to further compare the efficacy and safety of sintilimab with placebo, both in combination with GP.Methods ORIENT-12, a randomized, double-blind, phase 3 study, was conducted at 42 centers in the People's Republic of China (ClinicalTrials.gov, number NCT03629925). Patients with locally advanced or metastatic sqNSCLC and without EGFR-sensitive mutations or ALK rearrangements were enrolled in the study. The stratification factors included clinical stage, choice of platinum, and programmed death-ligand 1 tumor proportion score. The patients, investigators, research staff, and sponsor team were masked to treatment assignment. Eligible patients were randomized 1:1, using an integrated web-response system, to receive sintilimab 200 mg or placebo plus GP every 3 weeks for four or six cycles, followed by sintilimab or placebo as maintenance therapy until disease progression or 2 years. The primary end point was progression-free survival (PFS), assessed by an independent radiographic review committee.Results Between September 25, 2018 and July 26, 2019, a total of 543 patients were screened, of whom 357 patients were randomized to the sintilimab-GP group (n = 179) and the placebo-GP group (n = 178). After a median follow-up period of 12.9 months, sintilimab-GP continued to reveal a meaningful improvement in PFS than placebo-GP (hazard ratio = 0.536 [95% confidence interval: 0.422-0.681], p < 0.00001). Treatment-emergent adverse events of grade 3 or worse occurred in 86.6% patients in the sintilimab-GP group and in 83.1% in the placebo-GP group. The incidence of treatment-emergent adverse event leading to death was 4.5% and 6.7% in the two treatment groups, respectively.Conclusions Regarding PFS, sintilimab plus GP reveals clinical benefit than GP alone as first-line therapy in patients with locally advanced or metastatic sqNSCLC. The toxicity was acceptable, and no new unexpected safety signals were observed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2021.04.011

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203

Show all 38 references

Sorted by citations

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Non‐small cell lung cancer in China
Chen, P., Liu, Y., Wen, Y., & Zhou, C. (2022) · 癌症：英文版 · doi:10.1002/cac2.12359 · Cited by 694
Self-citation
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
Lü, Z., Wang, J., Shu, Y., Liu, L., Kong, L., Yang, L., Wang, B., Sun, G., Ji, Y., Cao, G., et al. (2022) · BMJ · doi:10.1136/bmj-2021-068714 · Cited by 495
Self-citation
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Fu, K., Xie, F., Wang, F., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01391-4 · Cited by 432
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
Ren, S., Chen, J., Xu, X., Jiang, T., Cheng, Y., Chen, G., Pan, Y., Fang, Y., Wang, Q., Huang, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.018 · Cited by 324
Self-citation
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
Zhou, Q., Chen, M., Jiang, O., Pan, Y., Hu, D., Lin, Q., Wu, G., Cui, J., Chang, J., Cheng, Y., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00630-6 · Cited by 261
Self-citation
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
Zhou, C., Wang, Z., Sun, Y., Cao, L., Ma, Z., Wu, R., Yu, Y., Yao, W., Chang, J., Chen, J., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00650-1 · Cited by 238
Self-citation
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Self-citation
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
Xiong, A., Wang, L., Chen, J., Wu, L., Liu, B., Yao, J., Zhong, H., Li, J., Cheng, Y., Sun, Y., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02722-3 · Cited by 173
Self-citation
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 185
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Shi, K., Wang, G., Pei, J., Zhang, J., Wang, J., Ouyang, L., Wang, Y., & Li, W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01311-6 · Cited by 174
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
Xu, J., Li, Y., Fan, Q., Shu, Y., Yang, L., Cui, T., Gu, K., Tao, M., Wang, X., Cui, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28408-3 · Cited by 146
Self-citation
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 131
Immunotherapy-based combinations in metastatic NSCLC
Desai, A. P., & Peters, S. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102545 · Cited by 94
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)
Zhou, C., Hu, Y., Arkania, E., Kılıçkap, S., Ying, K., Xu, F., Wu, L., Wang, X., Viguro, M., Makharadze, T., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.004 · Cited by 72
Self-citation
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
Zhong, H., Sun, S., Chen, J., Wang, Z., Zhao, Y., Zhang, G., Chen, G., Zhou, M., Zhou, J., Du, Y., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00431-9 · Cited by 64
Self-citation
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 74
Self-citation
Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)
Shi, Y., Wu, L., Yu, X., Xing, P., Wang, Y., Zhou, J., Wang, A., Shi, J., Hu, Y., Wang, Z., et al. (2022) · 癌症：英文版 · doi:10.1002/cac2.12385 · Cited by 61
Self-citation
Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review
Li, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4444 · Cited by 68
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial
Jiang, T., Chen, J., Xu, X., Cheng, Y., Chen, G., Pan, Y., Fang, Y., Wang, Q., Huang, Y., Yao, W., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01479-4 · Cited by 50
Self-citation
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
Reck, M., Frost, N., Peters, S., Fox, B. A., Ferrara, R., Savai, R., & Barlési, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01061-7 · Cited by 62
Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis
Zhao, M., Pan, X., Yin, Y., Hu, H., Wei, J., Bai, Z., & Tang, W. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.869960 · Cited by 48
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
Chen, Z., Yang, F., Jiang, Z., Sun, L., Wu, L., Han, Z., Fan, Y. L., Zhao, Y., Li, X., Xu, H., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01848-3 · Cited by 51
Self-citation
KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial
Zhao, Y., Chen, G., Li, X., Wu, J., Chang, B., Hu, S., Yang, S., Xu, T. S., Liu, Y., Wang, N., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101470 · Cited by 46
Self-citation
Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000–2025)
Huang, L., Zhu, H., & Shi, Y. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01734-x · Cited by 48
Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis
Wang, Y., Han, H., Zhang, F., Lv, T., Zhan, P., Ye, M., Song, Y., & Liu, H. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01832-4 · Cited by 44
Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors
Yan, T., Yu, L., Shangguan, D., Li, W., Liu, N., Chen, Y., Fu, Y., Tang, J., & Liao, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109638 · Cited by 45
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients
Zhou, X., Zhou, L., Yao, Z., Huang, M., Gong, Y., Zou, B., Zhu, J., Liu, Y., Peng, F., Zhang, Y., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0315 · Cited by 43
Self-citation
Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysis
Federico, A. D., Giglio, A. D., Gelsomino, F., Sperandi, F., Melotti, B., & Ardizzoni, A. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac205 · Cited by 40
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial
Liu, S. M., Huang, J., Deng, J., Xu, C., Yan, H., Yang, M., Li, Y.-S., Ke, E., Zheng, M.-Y., Wang, Z., et al. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.12.046 · Cited by 38
Self-citation
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
Xiong, A., Wang, J., & Zhou, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.757993 · Cited by 38
Self-citation
Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis
Xia, H., Zhang, W., Zhang, Y., Shang, X., Liu, Y., & Wang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.978069 · Cited by 37
Self-citation
Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies
Yusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02812-3 · Cited by 40
A Phase IB Trial of Autologous Cytokine‐Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death‐1, plus Chemotherapy in Patients with Advanced Non‐Small‐Cell Lung Cancer
Zhou, L., Xiong, Y., Wang, Y., Meng, Y. G., Zhang, W., Shen, M., Zhang, X., Li, S., Ren, B., Li, R., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.07.009 · Cited by 36
Self-citation
Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma
Duan, J., Zhang, Y., Chen, R., Liang, L., Huo, Y., Lü, S., Zhao, J., Hu, C., Sun, Y., Yang, K., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101302 · Cited by 35
Self-citation
Sintilimab for the treatment of non-small cell lung cancer
Zhang, L., Lin, W., Tan, F., Li, N., Xue, Q., Gao, S., Gao, Y., & He, J. (2022) · Biomarker Research · doi:10.1186/s40364-022-00363-7 · Cited by 36
Self-citation
A comprehensive review on targeting diverse immune cells for anticancer therapy: Beyond immune checkpoint inhibitors
Liu, D., Liu, L., Zhao, X., Zhang, X., Chen, X., Che, X., & Wu, G. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104702 · Cited by 40
Self-citation
Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events
Yan, T., Yu, L., Zhang, J., Chen, Y., Fu, Y., Tang, J., & Liao, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1292122 · Cited by 39
Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors
Rebuzzi, S. E., Prelaj, A., Friedlaender, A., Cortellini, A., Addeo, A., Genova, C., Naqash, A. R., Auclin, É., Mezquita, L., & Banna, G. L. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103806 · Cited by 34
Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial
Yan, W., Zhong, W., Liu, Y., Chen, Q., Xing, W., Zhang, Q., Liu, L., Ge, D., Chen, K., Yang, F., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.222 · Cited by 33
Self-citation
Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study
Li, R., Liang, H., Li, J., Shao, Z., Yang, D., Bao, J., Wang, K., Wen, X., Gao, Z., Guo, R., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-11860-3 · Cited by 31
Self-citation
Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
Shao, T., Ren, Y., Zhao, M., & Tang, W. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.912921 · Cited by 28
Tumor immunotherapy: Mechanisms and clinical applications
Nong, C., Guan, P., Li, L., Zhang, H., & Hu, H. (2022) · MedComm – Oncology · doi:10.1002/mog2.8 · Cited by 27
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives
Cella, E., Zullo, L., Marconi, S., Rossi, G., Coco, S., Dellepiane, C., Alama, A., Rozeboom, L. M., Bennicelli, E., Parisi, F., et al. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2116273 · Cited by 25
Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review
Wang, Y., Li, C., Wang, Z., Wang, Z., Wu, R., Wu, Y., Song, Y., & Liu, H. (2022) · BMC Medicine · doi:10.1186/s12916-022-02580-1 · Cited by 29
Self-citation
Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1–Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial
Reck, M., Barlési, F., Yang, J. C.-H., Westeel, V., Felip, E., Özgüroğlu, M., Cobo, M., Sullivan, R., Kowalski, D. M., Andric, Z. G., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.09.1445 · Cited by 27
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial
Zhong, J., Fei, K., Wu, L., Li, B., Wang, Z., Cheng, Y., Li, X., Wang, X., Han, L., Wu, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02087-6 · Cited by 29
Self-citation
Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial
Ma, S., He, Z., Liu, Y., Wang, L., Yang, S., Wu, Y., Chen, H., Wu, Y., & Wang, Q. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102543 · Cited by 25
Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations
Frost, N., & Reck, M. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432524 · Cited by 25
Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs
Dong, S., Li, X., Huang, Q., Li, Y., Li, J., Zhu, X., Xue, C., Chen, R., Zeng, Y., Wu, J., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101215 · Cited by 25
Self-citation
Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial
Han, X., Tang, X., Zhu, H., Zhu, D., Zhang, X., Meng, X., Hua, Y., Wang, Z., Zhang, Y., Huang, W., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004952 · Cited by 23
Self-citation
Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial
Ni, J., Wang, X., Wu, L., Ai, X., Chu, Q., Han, C., Dong, X., Zhou, Y., Pang, Y., & Zhu, Z. (2024) · Nature Communications · doi:10.1038/s41467-024-51807-7 · Cited by 24
Self-citation
Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
Chen, P., Wang, X., Zhu, S., Li, H., Rui, M., Wang, Y., Sun, H., & Ma, A. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.956792 · Cited by 22
Tumor Immune Microenvironment Predicts the Pathologic Response Of Neoadjuvant Chemoimmunotherapy In Locally Advanced And Oligometastatic Non–Small Cell Lung Cancer
Han, R. F., Zhang, Y., Wang, T., Xiao, H., Luo, Z., Shen, C., Li, J., Zhao, C., Li, L., Zhu, M., et al. (2022) · Cancer Science · doi:10.1111/cas.15778 · Cited by 20
Self-citation
Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis
Li, Y., Liang, X., Li, H., & Chen, X. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002750 · Cited by 26
Self-citation
Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)
Hu, X., Ren, J., Xue, Q., Luan, R., Ding, D., Tan, J., Su, X., & Yang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5570 · Cited by 22
Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma
Shao, T., Zhao, M., & Tang, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.953671 · Cited by 21
Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy
Jia, L., Chen, N., Chen, X., Niu, C. S., Liu, Z., Ma, K., Wang, N., Yang, L., Zhao, Y., Song, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1074906 · Cited by 21
Self-citation
Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
Krzyżanowska, N., Wojas‐Krawczyk, K., Milanowski, J., & Krawczyk, P. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063087 · Cited by 19
Immunotherapy combined with chemotherapy versus chemotherapy alone as the first‐line treatment of PD‐L1 ‐negative and driver‐gene‐negative advanced nonsquamous non‐small‐cell lung cancer: An updated systematic review and meta‐analysis
Chai, Y., Wu, X., Zou, Y., Zhang, X., Bai, H., Dong, M., & Duan, J. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14664 · Cited by 20
Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer
Song, L., Zeng, L., Yan, H., Xu, Q., Xia, Q., Lei, J., Chen, X., Hu, X., Wang, Z., Liu, H., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00206-4 · Cited by 20
Self-citation
Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis
Zhao, M., Shao, T., Ren, Y., Zhou, C., & Tang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.910656 · Cited by 19
Self-citation
Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model
Zhao, M., Shao, T., Chi, Z., & Tang, W. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1051484 · Cited by 19
Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study
Zhang, Y., Song, L., Zeng, L., Xiong, Y., Liu, L., Zhou, C., Yang, H., Wang, Z., Xia, Q., Jiang, W., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10045-0 · Cited by 19
Self-citation
CACA guidelines for holistic integrative management of lung cancer
Wang, J. (2024) · Holistic Integrative Oncology · doi:10.1007/s44178-024-00069-w · Cited by 19
KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape
Frisch, A., Martin, E., Kim, S. Y., Riess, J. W., Sen, T., & Karim, N. A. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf153 · Cited by 24
Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China
Mizuno, T., Katsuya, Y., Sato, J., Koyama, T., Shimizu, T., & Yamamoto, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.925938 · Cited by 21
Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer
Wang, F., Xia, T., Li, Z., Gao, X., & Fang, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1213297 · Cited by 19
Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review
Guo, H., Zhang, J., Qin, C., Yan, H., Luo, X., & Zhou, H. (2024) · Medicine · doi:10.1097/md.0000000000036861 · Cited by 19
Self-citation
Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy
Zhou, S., Ren, F., & Meng, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.955944 · Cited by 20
Emerging platinum(0) nanotherapeutics for efficient cancer therapy
Qiao, H., Chen, Z., Fu, S., Yu, X., Sun, M., Zhai, Y., & Sun, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.021 · Cited by 16
Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis
Li, F., Zhai, S., Lv, Z., Yuan, L., Wang, S., Jin, D., Yi, H., Fu, L., & Mao, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.968517 · Cited by 17
Self-citation
Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: a retrospective cohort study
Yin, C., Zou, G., He, Y., Li, J., Yan, H., Su, Z., Cao, X., & Li, X. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-387 · Cited by 18
Self-citation
Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review
Bai, Y., Yang, W., Käsmann, L., Sorich, M. J., Tao, H., & Hu, Y. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-144 · Cited by 17
Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study
Mao, C., Xiong, A., Qian, J., Wang, W., Liu, Y., Zhang, T., Wu, Z., Ni, H., Lu, J. E., Long, S., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01651-5 · Cited by 17
Self-citation
The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: A systematic review and network meta-analysis
Mei, T., Wang, T., Deng, Q., & Gong, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1062679 · Cited by 19
Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non–small cell lung cancer
Xu, L., Si, H., Zhuang, F., Li, C., Zhang, L., Zhao, Y., Chen, T., Dong, Y., Wang, T., Hou, L., et al. (2024) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2024.05.006 · Cited by 17
Self-citation
Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China
Xiang, Z., Ma, L., Fu, Y., & Pan, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1411571 · Cited by 16
Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1
Mor, A., & Strazza, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.790386 · Cited by 16
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
Xiong, A., Yao, W., Zheng, W., Yan, Y., Chen, P., Zhong, H., Ge, J., Wang, H., Chen, B., Wang, H., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00968-2 · Cited by 15
Self-citation
PD-1/PD-L1 inhibitors in treatment-naïve, advanced non-small cell lung cancer patients with < 1% PD-L1 expression: a meta-analysis of randomized controlled trials
Wankhede, D., Hofman, P. M., & Grover, S. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04286-6 · Cited by 15
Drug-eluting beads bronchial arterial chemoembolization/bronchial arterial infusion chemotherapy with and without PD-1 blockade for advanced non-small cell lung cancer: a comparative single-center cohort study
Xu, S., Li, Y., Bie, Z., & Li, X. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-23-287 · Cited by 15
Self-citation
Combining stereotactic body radiotherapy with immunotherapy in stage IV non-small cell lung cancer
Liu, X., & Chi, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1211815 · Cited by 15
The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
Wang, J., He, Y., Zhang, B., Lv, H., Nie, C., Chen, B., Xu, W., Zhao, J., Cheng, X., Li, Q., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924149 · Cited by 14
Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system
Liang, X., Xiao, H., Li, H., Chen, X., & Li, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1396752 · Cited by 14
Self-citation
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
Lu, S., Liu, B., Luo, Y., Sun, L., Wu, L., Han, Z., Fan, Y., Zhao, Y. W., Li, X., Xu, H., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00966-9 · Cited by 13
Self-citation
Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial
Chen, K., Xu, Y., Huang, Z., Yu, X., Hong, W., Li, H., Xu, X., Lu, H., Xie, F., Chen, J., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6548 · Cited by 13
Self-citation
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Pang, L., Gan, J., Huang, Y., Liao, J., Zhuang, W., Ali, W. A. S., Hong, S., Zhang, L., & Fang, W. (2023) · BMC Cancer · doi:10.1186/s12885-022-10446-1 · Cited by 13
Self-citation
Effect of PD-L1 Expression for the PD-1/L1 Inhibitors on Non-small Cell Lung Cancer: A Meta-analysis Based on Randomised Controlled Trials
Xu, Z., Liang, J., Fu, R., Yang, L., Chen, Y., Ren, W., Lü, Y., Qiu, X.-X., & Gu, Q. (2023) · Clinical Oncology · doi:10.1016/j.clon.2023.07.012 · Cited by 15
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis
Yang, Y., Chen, W., Dong, L., Duan, L., & Gao, P. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03442-3 · Cited by 15
Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies
Yang, X., Luo, B., Tian, J., Wang, Y., Lu, X., Ni, J., Yang, Y., Jiang, L., & Ren, S. (2025) · Biological Procedures Online · doi:10.1186/s12575-025-00287-0 · Cited by 13
Assessing the efficacy of immunotherapy in lung squamous carcinoma using artificial intelligence neural network
Li, S., Li, W., Ma, T., Fu, S., Gao, X., Qin, N., Wu, Y., Zhang, X., Wang, J., Pan, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1024707 · Cited by 13
Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: a phase 2 clinical trial
Zhang, M., Zhang, G., Niu, Y., Zhang, G., Ji, Y., Yan, X., Zhang, X., Wang, Q., Jing, X., Wang, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45769-z · Cited by 12
Comparative efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced driver-gene negative non-small cell lung cancer: A systematic review and network meta-analysis
Zhang, X., Wu, M., Chen, J., Zheng, K., Du, H., Li, B., Gu, Y., & Jiang, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30809 · Cited by 14
Self-citation
Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis
Chu, X., Tian, W., Ning, J., & Zhou, R. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae137 · Cited by 12
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia
Cheng, Y., Yang, J. C.-H., Okamoto, I., Zhang, L., Hu, J., Wang, D., Hu, C., Zhou, J., Wu, L., Cao, L., et al. (2023) · Immunotherapy · doi:10.2217/imt-2023-0043 · Cited by 12
Self-citation
Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC
Huang, Y., Chau, Y. F., Bai, H., Wu, X., & Duan, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914521 · Cited by 10
Value of prognostic nutritional index and controlling nutritional status score for advanced non-small cell lung cancer patients receiving PD-1 inhibitors
Jiang, S. (2024) · American Journal of Cancer Research · doi:10.62347/xqhl4852 · Cited by 11
Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer
Orillard, É., Adhikari, A., Malouf, R. S., Calais, F., Marchal, C., & Westeel, V. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015495 · Cited by 13
Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial
Chu, T., Zhong, H., Yu, Z., Wang, J., Zhao, Y., Mu, X., Yu, X., Shi, X., Shi, Q., Guan, M., et al. (2025) · 癌症：英文版 · doi:10.1002/cac2.12654 · Cited by 11

Authors: Zhou, C., Wu, L., Fan, Y., Wang, Z., Liu, L., Chen, G., Zhang, L., Huang, D., Cang, S., Yang, Z., Zhou, J., Zhou, C., Li, B., Li, J., Fan, M., Cui, J., Li, Y., Zhao, H., Fang, J., Xue, J., Hu, C., Sun, P., Du, Y., Zhou, H., Wang, S., & Zhang, W.
Affiliations: First Affiliated Hospital of Guangzhou Medical University (CN)
Hunan Cancer Hospital (CN)
University of Chinese Academy of Sciences (CN)
Shandong Tumor Hospital (CN)
Jiangsu Province Hospital (CN)
Harbin Medical University (CN)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Tianjin Medical University Cancer Institute and Hospital (CN)
Henan Provincial People's Hospital (CN)
Guangdong Medical College (CN)
First Affiliated Hospital Zhejiang University (CN)
Capital Medical University (CN)
Sichuan Cancer Hospital (CN)
Fudan University Shanghai Cancer Center (CN)
First Hospital of Jilin University (CN)
First Affiliated Hospital of Wenzhou Medical University (CN)
Second Affiliated Hospital of Anhui Medical University (CN)
Peking University Cancer Hospital (CN)
Sichuan University (CN)
Xiangya Hospital Central South University (CN)
Yuhuangding Hospital (CN)
First Affiliated Hospital of Anhui Medical University (CN)
Innovent Biologics (China) (CN)
Corresponding author: Zhou, Caicun
ORCID: Zhou, Caicun
Wu, Lin
Fan, Yun
Wang, Zhehai
Zhang, Li
Huang, Dingzhi
Cang, Shundong
Yang, Zhixiong
Zhou, Jianying
Zhou, Chengzhi
Li, Baolan
Li, Juan
Fan, Min
Cui, Jiuwei
Li, Yuping
Zhao, Hui
Fang, Jian
Xue, Jianxin
Hu, Chengping
Sun, Ping
Du, Yingying
Zhou, Hui
Wang, Shuyan
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2021-09
Volume: 16
Issue: 9
Pages: 1501-1511
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1016/j.jtho.2021.04.011
OpenAlex: W3165007730
Cited by: 322
References: 38
Citations by year: 2026: 42 · 2025: 62 · 2024: 71 · 2023: 70 · 2022: 71 · 2021: 6
FWCI: 19.84
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 366 d)
Locations: Journal of Thoracic Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Eli Lilly and Company
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: sintilimab, lung squamous cell carcinoma, first-line therapy, immune checkpoint inhibitors, PD-1 inhibitors, progression-free survival, maintenance therapy, treatment-emergent adverse events, EGFR wild-type
MeSH terms: Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Deoxycytidine, Double-Blind Method, Humans, Lung Neoplasms, Platinum, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks